113 related articles for article (PubMed ID: 30556932)
1. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
[TBL] [Abstract][Full Text] [Related]
3. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
[TBL] [Abstract][Full Text] [Related]
4. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
Ratai EM; Zhang Z; Fink J; Muzi M; Hanna L; Greco E; Richards T; Kim D; Andronesi OC; Mintz A; Kostakoglu L; Prah M; Ellingson B; Schmainda K; Sorensen G; Barboriak D; Mankoff D; Gerstner ER;
PLoS One; 2018; 13(6):e0198548. PubMed ID: 29902200
[TBL] [Abstract][Full Text] [Related]
5. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
[TBL] [Abstract][Full Text] [Related]
6. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
[TBL] [Abstract][Full Text] [Related]
7. Retrospective examination of pseudoprogression in
Wetzel EA; Farrell MJ; Eldred BSC; Liu V; Saha I; Zapanta Rinonos S; Prins T; Li T; Cao M; Hegde J; Kaprealian T; Khanlou N; Liau LM; Nghiemphu PL; Cloughesy TF; Chong RA; Ellingson BM; Lai A
Neurooncol Adv; 2023; 5(1):vdad028. PubMed ID: 37128507
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2023 Oct; ():. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
9. The role of 3-Tesla magnetic resonance perfusion and spectroscopy in distinguishing glioblastoma from solitary brain metastasis.
Hung ND; Dung LV; Vi NH; Hai Anh NT; Hong Phuong LT; Hieu ND; Duc NM
J Clin Imaging Sci; 2023; 13():19. PubMed ID: 37559877
[TBL] [Abstract][Full Text] [Related]
10. Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges.
Li K; Zhu Q; Yang J; Zheng Y; Du S; Song M; Peng Q; Yang R; Liu Y; Qi L
Acad Radiol; 2024 Apr; ():. PubMed ID: 38614827
[TBL] [Abstract][Full Text] [Related]
11. Applying a Radiation Therapy Volume Analysis Pipeline to Determine the Utility of Spectroscopic MRI-Guided Adaptive Radiation Therapy for Glioblastoma.
Trivedi AG; Kim SH; Ramesh KK; Giuffrida AS; Weinberg BD; Mellon EA; Kleinberg LR; Barker PB; Han H; Shu HG; Shim H; Schreibmann E
Tomography; 2023 May; 9(3):1052-1061. PubMed ID: 37218946
[TBL] [Abstract][Full Text] [Related]
12. Low-parameter supervised learning models can discriminate pseudoprogression and true progression in non-perfusion-based MRI.
Warner E; Lee J; Krishnan S; Wang N; Mohammed S; Srinivasan A; Bapuraj J; Rao A
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38083692
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma.
Jang BS; Jeon SH; Kim IH; Kim IA
Sci Rep; 2018 Aug; 8(1):12516. PubMed ID: 30131513
[TBL] [Abstract][Full Text] [Related]
14. Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps.
Cuccarini V; Savoldi F; Mardor Y; Last D; Pellegatta S; Mazzi F; Bruzzone MG; Anghileri E; Pollo B; Maddaloni L; Russo C; Bocchi E; Pinzi V; Eoli M; Aquino D
Front Neurol; 2024; 15():1374737. PubMed ID: 38651109
[TBL] [Abstract][Full Text] [Related]
15. The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma.
Rejimon AC; Ramesh KK; Trivedi AG; Huang V; Schreibmann E; Weinberg BD; Kleinberg LR; Shu HG; Shim H; Olson JJ
Tomography; 2024 Mar; 10(3):428-443. PubMed ID: 38535775
[TBL] [Abstract][Full Text] [Related]
16. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.
Young JS; Al-Adli N; Scotford K; Cha S; Berger MS
J Neurosurg; 2023 Sep; 139(3):748-759. PubMed ID: 36790010
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study.
Blakstad H; Mendoza Mireles EE; Heggebø LC; Magelssen H; Sprauten M; Johannesen TB; Vik-Mo EO; Leske H; Niehusmann P; Skogen K; Helseth E; Emblem KE; Brandal P
Neurooncol Pract; 2024 Feb; 11(1):36-45. PubMed ID: 38222046
[TBL] [Abstract][Full Text] [Related]
18. Spectroscopic MRI-Guided Proton Therapy in Non-Enhancing Pediatric High-Grade Glioma.
Huang V; Rejimon A; Reddy K; Trivedi AG; Ramesh KK; Giuffrida AS; Muiruri R; Shim H; Eaton BR
Tomography; 2023 Mar; 9(2):633-646. PubMed ID: 36961010
[TBL] [Abstract][Full Text] [Related]
19. MRI phenotypes of glioblastomas early after treatment are suggestive of overall patient survival.
Schmitz-Abecassis B; Dirven L; Jiang J; Keller JA; Croese RJI; van Dorth D; Ghaznawi R; Kant IMJ; Taphoorn MJB; van Osch MJP; Koekkoek JAF; de Bresser J
Neurooncol Adv; 2023; 5(1):vdad133. PubMed ID: 37908765
[TBL] [Abstract][Full Text] [Related]
20. Combined
D'Amore F; Grinberg F; Mauler J; Galldiks N; Blazhenets G; Farrher E; Filss C; Stoffels G; Mottaghy FM; Lohmann P; Shah NJ; Langen KJ
Neurooncol Adv; 2021; 3(1):vdab044. PubMed ID: 34013207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
